it can't wait.
Ask your doctor if your chronic
reflux could be putting your
health and life at risk.
Years of chronic reflux can lead to Barrett’s esophagus, a precursor to esophageal cancer.1 Over time, a constant backwash of stomach acid can cause the lining of the esophagus to change. Symptoms may not be obvious, so it's possible to develop Barrett's esophagus or esophageal adenocarcinoma without knowing it.1
While prevalence of Barrett’s esophagus is low in the general population, it’s higher in GERD patients.1
If you’ve been living with chronic reflux for years, talk to your doctor.
If you’ve been diagnosed with Barrett’s, odds are, it can’t wait. Talk to your GI about treatment options.
A variety of factors may contribute to increased risk for progression to Barrett's esophagus or esophageal adenocarcinoma (EAC):3
If you have Barrett’s, watching and waiting isn’t always effective because the disease can progress quickly between endoscopy appointments.9, 10
Talk to your GI about a more proactive approach:
Barrx™ radiofrequency ablation system
The following are transient side effects that may be expected after treatment: chest pain, difficulty swallowing, painful swallowing, throat pain, and/or fever.
Potential complications include mucosal laceration, minor or major bleeding, endoscopic clipping to manage mucosal laceration or bleeding, perforation of the stomach, esophagus or pharynx, surgery to manage perforation, esophageal stricture, endoscopic dilation to manage stricture, pleural effusion, transfusion secondary to major bleeding, cardia arrhythmia, aspiration, infection and death.
94% is the calculated relative risk reduction [ (26-1.5)/26] = 25/26 *100. From [25.0% (1.5% for ablation versus 26.5% for control; 95% CI, 14.1%-35.9%; P < .001].
Dam AN, Klapman J. A narrative review of Barrett’s esophagus in 2020, molecular and clinical update. Annals of Translational Medicine. 2020;8(17):1107.
Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-717.
Muñoz-Largacha JA, Fernando HC, Litle VR. Optimizing the diagnosis and therapy of Barrett’s esophagus. Journal of Thoracic Disease. 2017;9(Suppl 2):S146-S153.
Labenz J, Chandrasoma PT, Knapp LJ, DeMeester TR. Proposed approach to the challenging management of progressive gastroesophageal reflux disease. World Journal of Gastrointestinal Endoscopy. 2018;10(9):175-183.
Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med 2014;371:836-45.
Schlottmann F, Patti MG. From heartburn to Barrett’s esophagus, and beyond. World Journal of Surgery. Jul;41(7):1398-1704.
Tofani CJ, Gandhi K, Spataro J, et,al. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus. United European Gastroenterol J. 2019 Mar;7(2):225-229.
Phoa KN, van Vilsteren FG, Pouw RE, Weusten BL, Bisschops R, Schoon EJ, et al. Radiofrequency ablation versus endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–17.
Fleischer DE et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett’s esophagus. Dig Dis Sci 2010; 55(7):1918-31.
Wolf WA, Pasricha S, Cotton C, et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett's esophagus. Gastroenterology. 2015;149:1752-1761.
US-SE-2200052 ©2022 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.